{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T17:11:45Z","timestamp":1781629905800,"version":"3.54.5"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T00:00:00Z","timestamp":1768348800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":23,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"NCI"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Late detection and tumor recurrence are major factors driving the lethality of high-grade serous ovarian carcinoma (HGSOC). PARP inhibitors (PARPi) have achieved significant clinical efficacy by selectively targeting DNA repair deficiencies in HGSOC patients with\n                    <jats:italic>BRCA<\/jats:italic>\n                    mutations and homologous recombination deficiency (HRD). However, a subset of patients ultimately develops resistance to PARPi, necessitating alternative effective treatment options. The mutational signatures of APOBEC3 family of DNA deaminases are widespread across a broad array of cancer types. Here, we report that cancer stem cell (CSC)-like tumorspheres exhibit reduced A3B expression compared to non-CSC adherent counterparts. Importantly, inhibition of A3B leads to PARPi resistance, elevated frequency of CSCs, and enhanced expression of stemness factors. In addition, we found that high A3B-expressing cells are under strong replication stress and thus synergize efficiently with PARPi. These studies reveal the important role A3B plays in regulating PARPi response.\n                  <\/jats:p>","DOI":"10.1038\/s41598-026-35939-y","type":"journal-article","created":{"date-parts":[[2026,1,14]],"date-time":"2026-01-14T06:45:47Z","timestamp":1768373147000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["APOBEC3B enhances the efficacy of PARP inhibitors in elimination of ovarian cancer stem cell"],"prefix":"10.1038","volume":"16","author":[{"given":"Maria","family":"Rivera","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabina","family":"Enlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chae-Eun","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaifu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roman","family":"Sasik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie A.","family":"Crews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathleen M.","family":"Fisch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramez N.","family":"Eskander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frida","family":"Holm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingfei","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,14]]},"reference":[{"key":"35939_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/nature03443","volume":"434","author":"HE Bryant","year":"2005","unstructured":"Bryant, H. E. et al. Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase. Nature 434, 913\u2013917. https:\/\/doi.org\/10.1038\/nature03443 (2005).","journal-title":"Nature"},{"key":"35939_CR2","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/nature03445","volume":"434","author":"H Farmer","year":"2005","unstructured":"Farmer, H. et al. Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature 434, 917\u2013921. https:\/\/doi.org\/10.1038\/nature03445 (2005).","journal-title":"Nature"},{"key":"35939_CR3","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/S1470-2045(17)30469-2","volume":"18","author":"E Pujade-Lauraine","year":"2017","unstructured":"Pujade-Lauraine, E. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 18, 1274\u20131284. https:\/\/doi.org\/10.1016\/S1470-2045(17)30469-2 (2017).","journal-title":"Lancet Oncol"},{"key":"35939_CR4","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","volume":"22","author":"A Poveda","year":"2021","unstructured":"Poveda, A. et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol 22, 620\u2013631. https:\/\/doi.org\/10.1016\/S1470-2045(21)00073-5 (2021).","journal-title":"Lancet Oncol"},{"key":"35939_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082054","author":"EK Lee","year":"2020","unstructured":"Lee, E. K. & Matulonis, U. A. PARP Inhibitor resistance mechanisms and implications for post-progression combination therapies. Cancers (Basel) https:\/\/doi.org\/10.3390\/cancers12082054 (2020).","journal-title":"Cancers (Basel)"},{"key":"35939_CR6","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1016\/j.ajog.2011.03.008","volume":"204","author":"R Salani","year":"2011","unstructured":"Salani, R. et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 204, 466\u2013478. https:\/\/doi.org\/10.1016\/j.ajog.2011.03.008 (2011).","journal-title":"Am J Obstet Gynecol"},{"key":"35939_CR7","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1158\/2159-8290.CD-15-0714","volume":"5","author":"PA Konstantinopoulos","year":"2015","unstructured":"Konstantinopoulos, P. A., Ceccaldi, R., Shapiro, G. I. & D\u2019Andrea, A. D. Homologous recombination deficiency: Exploiting the fundamental vulnerability of ovarian cancer. Cancer Discov 5, 1137\u20131154. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0714 (2015).","journal-title":"Cancer Discov"},{"key":"35939_CR8","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1097\/AOG.0000000000001623","volume":"128","author":"BY Karlan","year":"2016","unstructured":"Karlan, B. Y., Alvarez, R. D. & Strauss, J. F. 3rd. Evolving paradigms in research and care in ovarian cancers. Obstet Gynecol 128, 771\u2013774. https:\/\/doi.org\/10.1097\/AOG.0000000000001623 (2016).","journal-title":"Obstet Gynecol"},{"key":"35939_CR9","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/GCO.0000000000000340","volume":"29","author":"PT Kroeger Jr","year":"2017","unstructured":"Kroeger, P. T. Jr. & Drapkin, R. Pathogenesis and heterogeneity of ovarian cancer. Curr Opin Obstet Gynecol 29, 26\u201334. https:\/\/doi.org\/10.1097\/GCO.0000000000000340 (2017).","journal-title":"Curr Opin Obstet Gynecol"},{"key":"35939_CR10","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1038\/nrc3432","volume":"13","author":"E Kipps","year":"2013","unstructured":"Kipps, E., Tan, D. S. & Kaye, S. B. Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer 13, 273\u2013282. https:\/\/doi.org\/10.1038\/nrc3432 (2013).","journal-title":"Nat Rev Cancer"},{"key":"35939_CR11","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/j.ygyno.2013.03.021","volume":"130","author":"N Auersperg","year":"2013","unstructured":"Auersperg, N. Ovarian surface epithelium as a source of ovarian cancers: unwarranted speculation or evidence-based hypothesis?. Gynecol Oncol 130, 246\u2013251. https:\/\/doi.org\/10.1016\/j.ygyno.2013.03.021 (2013).","journal-title":"Gynecol Oncol"},{"key":"35939_CR12","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrc4019","volume":"15","author":"DD Bowtell","year":"2015","unstructured":"Bowtell, D. D. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer 15, 668\u2013679. https:\/\/doi.org\/10.1038\/nrc4019 (2015).","journal-title":"Nat Rev Cancer"},{"key":"35939_CR13","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/497429","volume":"2010","author":"K Ushijima","year":"2010","unstructured":"Ushijima, K. Treatment for recurrent ovarian cancer-at first relapse. J Oncol 2010, 497429. https:\/\/doi.org\/10.1155\/2010\/497429 (2010).","journal-title":"J Oncol"},{"key":"35939_CR14","doi-asserted-by":"publisher","first-page":"4311","DOI":"10.1158\/0008-5472.CAN-08-0364","volume":"68","author":"S Zhang","year":"2008","unstructured":"Zhang, S. et al. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer Res 68, 4311\u20134320. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0364 (2008).","journal-title":"Cancer Res"},{"key":"35939_CR15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/nm1379","volume":"12","author":"K Polyak","year":"2006","unstructured":"Polyak, K. & Hahn, W. C. Roots and stems: stem cells in cancer. Nat. Med. 12, 296\u2013300. https:\/\/doi.org\/10.1038\/nm1379 (2006).","journal-title":"Nat. Med."},{"key":"35939_CR16","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1038\/nm.4409","volume":"23","author":"E Batlle","year":"2017","unstructured":"Batlle, E. & Clevers, H. Cancer stem cells revisited. Nat. Med. 23, 1124\u20131134. https:\/\/doi.org\/10.1038\/nm.4409 (2017).","journal-title":"Nat. Med."},{"key":"35939_CR17","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature12477","volume":"500","author":"LB Alexandrov","year":"2013","unstructured":"Alexandrov, L. B. et al. Signatures of mutational processes in human cancer. Nature 500, 415\u2013421. https:\/\/doi.org\/10.1038\/nature12477 (2013).","journal-title":"Nature"},{"key":"35939_CR18","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1038\/ng.3441","volume":"47","author":"LB Alexandrov","year":"2015","unstructured":"Alexandrov, L. B. et al. Clock-like mutational processes in human somatic cells. Nat Genet 47, 1402\u20131407. https:\/\/doi.org\/10.1038\/ng.3441 (2015).","journal-title":"Nat Genet"},{"key":"35939_CR19","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1038\/s41586-022-04972-y","volume":"607","author":"M Petljak","year":"2022","unstructured":"Petljak, M. et al. Mechanisms of APOBEC3 mutagenesis in human cancer cells. Nature 607, 799\u2013807. https:\/\/doi.org\/10.1038\/s41586-022-04972-y (2022).","journal-title":"Nature"},{"key":"35939_CR20","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1038\/s41586-024-07368-2","volume":"629","author":"S Senkin","year":"2024","unstructured":"Senkin, S. et al. Geographic variation of mutagenic exposures in kidney cancer genomes. Nature 629, 910\u2013918. https:\/\/doi.org\/10.1038\/s41586-024-07368-2 (2024).","journal-title":"Nature"},{"key":"35939_CR21","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/s41586-025-09219-0","volume":"644","author":"M Diaz-Gay","year":"2025","unstructured":"Diaz-Gay, M. et al. The mutagenic forces shaping the genomes of lung cancer in never smokers. Nature 644, 133\u2013144. https:\/\/doi.org\/10.1038\/s41586-025-09219-0 (2025).","journal-title":"Nature"},{"key":"35939_CR22","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/ng.2702","volume":"45","author":"SA Roberts","year":"2013","unstructured":"Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nat Genet 45, 970\u2013976. https:\/\/doi.org\/10.1038\/ng.2702 (2013).","journal-title":"Nat Genet"},{"key":"35939_CR23","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1005958","volume":"12","author":"RS Harris","year":"2016","unstructured":"Harris, R. S. & Anderson, B. D. Evolutionary paradigms from ancient and ongoing conflicts between the lentiviral vif protein and mammalian APOBEC3 enzymes. PLoS Pathog 12, e1005958. https:\/\/doi.org\/10.1371\/journal.ppat.1005958 (2016).","journal-title":"PLoS Pathog"},{"key":"35939_CR24","doi-asserted-by":"publisher","first-page":"36427","DOI":"10.1074\/jbc.M111.251058","volume":"286","author":"S Wissing","year":"2011","unstructured":"Wissing, S., Montano, M., Garcia-Perez, J. L., Moran, J. V. & Greene, W. C. Endogenous APOBEC3B restricts LINE-1 retrotransposition in transformed cells and human embryonic stem cells. J Biol Chem 286, 36427\u201336437. https:\/\/doi.org\/10.1074\/jbc.M111.251058 (2011).","journal-title":"J Biol Chem"},{"key":"35939_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101211","volume":"4","author":"C Durfee","year":"2023","unstructured":"Durfee, C. et al. Human APOBEC3B promotes tumor development in vivo including signature mutations and metastases. Cell Rep Med 4, 101211. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101211 (2023).","journal-title":"Cell Rep Med"},{"key":"35939_CR26","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20200261","author":"EK Law","year":"2020","unstructured":"Law, E. K. et al. APOBEC3A catalyzes mutation and drives carcinogenesis in vivo. J Exp Med https:\/\/doi.org\/10.1084\/jem.20200261 (2020).","journal-title":"J Exp Med"},{"key":"35939_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1038\/s41586-020-1969-6","volume":"578","author":"I.T.P.-C.A.o.W.G","year":"2020","unstructured":"Consortium & I.T.P.-C.A.o.W.G,. Pan-cancer analysis of whole genomes. Nature 578, 82\u201393. https:\/\/doi.org\/10.1038\/s41586-020-1969-6 (2020).","journal-title":"Nature"},{"key":"35939_CR28","doi-asserted-by":"publisher","first-page":"7222","DOI":"10.1158\/0008-5472.CAN-13-1753","volume":"73","author":"B Leonard","year":"2013","unstructured":"Leonard, B. et al. APOBEC3B upregulation and genomic mutation patterns in serous ovarian carcinoma. Cancer Res 73, 7222\u20137231. https:\/\/doi.org\/10.1158\/0008-5472.CAN-13-1753 (2013).","journal-title":"Cancer Res"},{"key":"35939_CR29","first-page":"405","volume":"34","author":"U Ruder","year":"2019","unstructured":"Ruder, U. et al. APOBEC3B protein expression and mRNA analyses in patients with high-grade serous ovarian carcinoma. Histol Histopathol 34, 405\u2013417 (2019).","journal-title":"Histol Histopathol"},{"key":"35939_CR30","doi-asserted-by":"publisher","first-page":"e1601737","DOI":"10.1126\/sciadv.1601737","volume":"2","author":"EK Law","year":"2016","unstructured":"Law, E. K. et al. The DNA cytosine deaminase APOBEC3B promotes tamoxifen resistance in ER-positive breast cancer. Sci Adv 2, e1601737. https:\/\/doi.org\/10.1126\/sciadv.1601737 (2016).","journal-title":"Sci Adv"},{"key":"35939_CR31","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1158\/2159-8290.CD-15-0344","volume":"5","author":"C Swanton","year":"2015","unstructured":"Swanton, C., McGranahan, N., Starrett, G. J. & Harris, R. S. APOBEC enzymes: mutagenic fuel for cancer evolution and heterogeneity. Cancer Discov 5, 704\u2013712. https:\/\/doi.org\/10.1158\/2159-8290.CD-15-0344 (2015).","journal-title":"Cancer Discov"},{"key":"35939_CR32","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1038\/s41588-020-0674-6","volume":"52","author":"D Mas-Ponte","year":"2020","unstructured":"Mas-Ponte, D. & Supek, F. DNA mismatch repair promotes APOBEC3-mediated diffuse hypermutation in human cancers. Nat Genet 52, 958\u2013968. https:\/\/doi.org\/10.1038\/s41588-020-0674-6 (2020).","journal-title":"Nat Genet"},{"key":"35939_CR33","doi-asserted-by":"publisher","first-page":"e00534","DOI":"10.7554\/eLife.00534","volume":"2","author":"BJ Taylor","year":"2013","unstructured":"Taylor, B. J. et al. DNA deaminases induce break-associated mutation showers with implication of APOBEC3B and 3A in breast cancer kataegis. Elife 2, e00534. https:\/\/doi.org\/10.7554\/eLife.00534 (2013).","journal-title":"Elife"},{"key":"35939_CR34","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1038\/embor.2011.46","volume":"12","author":"S Landry","year":"2011","unstructured":"Landry, S., Narvaiza, I., Linfesty, D. C. & Weitzman, M. D. APOBEC3A can activate the DNA damage response and cause cell-cycle arrest. EMBO Rep 12, 444\u2013450. https:\/\/doi.org\/10.1038\/embor.2011.46 (2011).","journal-title":"EMBO Rep"},{"key":"35939_CR35","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1080\/15384101.2016.1152426","volume":"15","author":"AM Green","year":"2016","unstructured":"Green, A. M. et al. APOBEC3A damages the cellular genome during DNA replication. Cell Cycle 15, 998\u20131008. https:\/\/doi.org\/10.1080\/15384101.2016.1152426 (2016).","journal-title":"Cell Cycle"},{"key":"35939_CR36","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1038\/nature11881","volume":"494","author":"MB Burns","year":"2013","unstructured":"Burns, M. B. et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 494, 366\u2013370. https:\/\/doi.org\/10.1038\/nature11881 (2013).","journal-title":"Nature"},{"key":"35939_CR37","doi-asserted-by":"publisher","first-page":"zcaa033","DOI":"10.1093\/narcan\/zcaa033","volume":"2","author":"KL Conner","year":"2020","unstructured":"Conner, K. L. et al. APOBEC3 enzymes mediate efficacy of cisplatin and are epistatic with base excision repair and mismatch repair in platinum response. NAR Cancer 2, zcaa033 (2020).","journal-title":"NAR Cancer"},{"key":"35939_CR38","doi-asserted-by":"publisher","first-page":"4567","DOI":"10.1158\/0008-5472.CAN-16-3389","volume":"77","author":"R Buisson","year":"2017","unstructured":"Buisson, R., Lawrence, M. S., Benes, C. H. & Zou, L. APOBEC3A and APOBEC3B activities render cancer cells susceptible to ATR inhibition. Cancer Res 77, 4567\u20134578. https:\/\/doi.org\/10.1158\/0008-5472.CAN-16-3389 (2017).","journal-title":"Cancer Res"},{"key":"35939_CR39","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1038\/s41591-020-0926-0","volume":"26","author":"B Izar","year":"2020","unstructured":"Izar, B. et al. A single-cell landscape of high-grade serous ovarian cancer. Nat. Med. 26, 1271\u20131279. https:\/\/doi.org\/10.1038\/s41591-020-0926-0 (2020).","journal-title":"Nat. Med."},{"key":"35939_CR40","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ygyno.2013.12.001","volume":"132","author":"MM Shah","year":"2014","unstructured":"Shah, M. M. & Landen, C. N. Ovarian cancer stem cells: are they real and why are they important?. Gynecol Oncol 132, 483\u2013489. https:\/\/doi.org\/10.1016\/j.ygyno.2013.12.001 (2014).","journal-title":"Gynecol Oncol"},{"key":"35939_CR41","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3390\/cancers13020262","volume":"13","author":"M Robinson","year":"2021","unstructured":"Robinson, M. et al. Characterization of SOX2, OCT4 and NANOG in Ovarian Cancer Tumor-Initiating Cells. Cancers (Basel) 13, 4. https:\/\/doi.org\/10.3390\/cancers13020262 (2021).","journal-title":"Cancers (Basel)"},{"key":"35939_CR42","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1111\/cas.13186","volume":"108","author":"Y Wen","year":"2017","unstructured":"Wen, Y., Hou, Y., Huang, Z., Cai, J. & Wang, Z. SOX2 is required to maintain cancer stem cells in ovarian cancer. Cancer Sci 108, 719\u2013731. https:\/\/doi.org\/10.1111\/cas.13186 (2017).","journal-title":"Cancer Sci"},{"key":"35939_CR43","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/s41586-023-06303-1","volume":"620","author":"H Isozaki","year":"2023","unstructured":"Isozaki, H. et al. Therapy-induced APOBEC3A drives evolution of persistent cancer cells. Nature 620, 393\u2013401. https:\/\/doi.org\/10.1038\/s41586-023-06303-1 (2023).","journal-title":"Nature"},{"key":"35939_CR44","doi-asserted-by":"publisher","first-page":"2572","DOI":"10.1128\/MCB.01611-06","volume":"27","author":"H Niida","year":"2007","unstructured":"Niida, H., Katsuno, Y., Banerjee, B., Hande, M. P. & Nakanishi, M. Specific role of Chk1 phosphorylations in cell survival and checkpoint activation. Mol Cell Biol 27, 2572\u20132581. https:\/\/doi.org\/10.1128\/MCB.01611-06 (2007).","journal-title":"Mol Cell Biol"},{"key":"35939_CR45","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","volume":"108","author":"J Smith","year":"2010","unstructured":"Smith, J., Tho, L. M., Xu, N. & Gillespie, D. A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 108, 73\u2013112. https:\/\/doi.org\/10.1016\/B978-0-12-380888-2.00003-0 (2010).","journal-title":"Adv Cancer Res"},{"key":"35939_CR46","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1016\/j.ccr.2010.10.034","volume":"18","author":"M Squatrito","year":"2010","unstructured":"Squatrito, M. et al. Loss of ATM\/Chk2\/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell 18, 619\u2013629. https:\/\/doi.org\/10.1016\/j.ccr.2010.10.034 (2010).","journal-title":"Cancer Cell"},{"key":"35939_CR47","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncb3452","volume":"19","author":"N Hustedt","year":"2016","unstructured":"Hustedt, N. & Durocher, D. The control of DNA repair by the cell cycle. Nat. Cell Biol. 19, 1\u20139. https:\/\/doi.org\/10.1038\/ncb3452 (2016).","journal-title":"Nat. Cell Biol."},{"key":"35939_CR48","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s12943-020-01227-0","volume":"19","author":"H Li","year":"2020","unstructured":"Li, H. et al. PARP inhibitor resistance: the underlying mechanisms and clinical implications. Mol Cancer 19, 107. https:\/\/doi.org\/10.1186\/s12943-020-01227-0 (2020).","journal-title":"Mol Cancer"},{"key":"35939_CR49","doi-asserted-by":"publisher","first-page":"3726","DOI":"10.1038\/s41467-020-17127-2","volume":"11","author":"H Kim","year":"2020","unstructured":"Kim, H. et al. Combining PARP with ATR inhibition overcomes PARP inhibitor and platinum resistance in ovarian cancer models. Nat Commun 11, 3726. https:\/\/doi.org\/10.1038\/s41467-020-17127-2 (2020).","journal-title":"Nat Commun"},{"key":"35939_CR50","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.bbrc.2021.02.008","volume":"546","author":"S Hirabayashi","year":"2021","unstructured":"Hirabayashi, S. et al. APOBEC3B is preferentially expressed at the G2\/M phase of cell cycle. Biochem Biophys Res Commun 546, 178\u2013184. https:\/\/doi.org\/10.1016\/j.bbrc.2021.02.008 (2021).","journal-title":"Biochem Biophys Res Commun"},{"key":"35939_CR51","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1093\/nar\/gkq1241","volume":"39","author":"CE Strom","year":"2011","unstructured":"Strom, C. E. et al. Poly (ADP-ribose) polymerase (PARP) is not involved in base excision repair but PARP inhibition traps a single-strand intermediate. Nucleic Acids Res 39, 3166\u20133175. https:\/\/doi.org\/10.1093\/nar\/gkq1241 (2011).","journal-title":"Nucleic Acids Res"},{"key":"35939_CR52","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1038\/nrm.2017.53","volume":"18","author":"A Ray Chaudhuri","year":"2017","unstructured":"Ray Chaudhuri, A. & Nussenzweig, A. The multifaceted roles of PARP1 in DNA repair and chromatin remodelling. Nat Rev Mol Cell Biol 18, 610\u2013621. https:\/\/doi.org\/10.1038\/nrm.2017.53 (2017).","journal-title":"Nat Rev Mol Cell Biol"},{"key":"35939_CR53","doi-asserted-by":"publisher","first-page":"102905","DOI":"10.1016\/j.dnarep.2020.102905","volume":"94","author":"M Petljak","year":"2020","unstructured":"Petljak, M. & Maciejowski, J. Molecular origins of APOBEC-associated mutations in cancer. DNA Repair (Amst) 94, 102905. https:\/\/doi.org\/10.1016\/j.dnarep.2020.102905 (2020).","journal-title":"DNA Repair (Amst)"},{"key":"35939_CR54","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.bbrep.2018.10.010","volume":"16","author":"A Shimizu","year":"2018","unstructured":"Shimizu, A. et al. Onset of deaminase APOBEC3B induction in response to DNA double-strand breaks. Biochem Biophys Rep 16, 115\u2013121. https:\/\/doi.org\/10.1016\/j.bbrep.2018.10.010 (2018).","journal-title":"Biochem Biophys Rep"},{"key":"35939_CR55","doi-asserted-by":"publisher","first-page":"22158","DOI":"10.1073\/pnas.1904024116","volume":"116","author":"AA Serebrenik","year":"2019","unstructured":"Serebrenik, A. A. et al. The deaminase APOBEC3B triggers the death of cells lacking uracil DNA glycosylase. Proc. Natl. Acad. Sci. U.S.A. 116, 22158\u201322163. https:\/\/doi.org\/10.1073\/pnas.1904024116 (2019).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"35939_CR56","doi-asserted-by":"publisher","first-page":"108670","DOI":"10.1016\/j.celrep.2020.108670","volume":"34","author":"Q Jiang","year":"2021","unstructured":"Jiang, Q. et al. Inflammation-driven deaminase deregulation fuels human pre-leukemia stem cell evolution. Cell Rep 34, 108670. https:\/\/doi.org\/10.1016\/j.celrep.2020.108670 (2021).","journal-title":"Cell Rep"},{"key":"35939_CR57","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1158\/1078-0432.CCR-22-2861","volume":"29","author":"PA Roelofs","year":"2023","unstructured":"Roelofs, P. A., Martens, J. W. M., Harris, R. S. & Span, P. N. Clinical implications of APOBEC3-mediated mutagenesis in breast cancer. Clin Cancer Res 29, 1658\u20131669. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-2861 (2023).","journal-title":"Clin Cancer Res"},{"issue":"81\u201394","key":"35939_CR58","doi-asserted-by":"publisher","first-page":"e87","DOI":"10.1016\/j.ccell.2018.11.017","volume":"35","author":"Q Jiang","year":"2019","unstructured":"Jiang, Q. et al. Hyper-editing of cell-cycle regulatory and tumor suppressor rna promotes malignant progenitor propagation. Cancer Cell 35(81\u201394), e87. https:\/\/doi.org\/10.1016\/j.ccell.2018.11.017 (2019).","journal-title":"Cancer Cell"},{"key":"35939_CR59","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen, S., Zhou, Y., Chen, Y. & Gu, J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics 34, i884\u2013i890. https:\/\/doi.org\/10.1093\/bioinformatics\/bty560 (2018).","journal-title":"Bioinformatics"},{"key":"35939_CR60","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/nbt.3519","volume":"34","author":"NL Bray","year":"2016","unstructured":"Bray, N. L., Pimentel, H., Melsted, P. & Pachter, L. Near-optimal probabilistic RNA-seq quantification. Nat Biotechnol 34, 525\u2013527. https:\/\/doi.org\/10.1038\/nbt.3519 (2016).","journal-title":"Nat Biotechnol"},{"key":"35939_CR61","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1186\/s13059-016-0953-9","volume":"17","author":"J Xin","year":"2016","unstructured":"Xin, J. et al. High-performance web services for querying gene and variant annotation. Genome Biol 17, 91. https:\/\/doi.org\/10.1186\/s13059-016-0953-9 (2016).","journal-title":"Genome Biol"},{"key":"35939_CR62","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1093\/nar\/gkv007","volume":"43","author":"ME Ritchie","year":"2015","unstructured":"Ritchie, M. E. et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res 43, e47. https:\/\/doi.org\/10.1093\/nar\/gkv007 (2015).","journal-title":"Nucleic Acids Res"},{"key":"35939_CR63","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian, A. et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. U.S.A. 102, 15545\u201315550. https:\/\/doi.org\/10.1073\/pnas.0506580102 (2005).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"35939_CR64","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/nar\/28.1.27","volume":"28","author":"M Kanehisa","year":"2000","unstructured":"Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28, 27\u201330. https:\/\/doi.org\/10.1093\/nar\/28.1.27 (2000).","journal-title":"Nucleic Acids Res"},{"key":"35939_CR65","doi-asserted-by":"publisher","first-page":"1947","DOI":"10.1002\/pro.3715","volume":"28","author":"M Kanehisa","year":"2019","unstructured":"Kanehisa, M. Toward understanding the origin and evolution of cellular organisms. Protein Sci 28, 1947\u20131951. https:\/\/doi.org\/10.1002\/pro.3715 (2019).","journal-title":"Protein Sci"},{"key":"35939_CR66","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkae909","volume":"53","author":"M Kanehisa","year":"2025","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Matsuura, Y. & Ishiguro-Watanabe, M. KEGG: biological systems database as a model of the real world. Nucleic Acids Res 53, D672\u2013D677. https:\/\/doi.org\/10.1093\/nar\/gkae909 (2025).","journal-title":"Nucleic Acids Res"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35939-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35939-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35939-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:43:12Z","timestamp":1781628192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-35939-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,14]]},"references-count":66,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["35939"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-35939-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,14]]},"assertion":[{"value":"30 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5194"}}